Cargando…
Novel Insights into the Role of the Mineralocorticoid Receptor in Human Glioblastoma
The majority of glioblastoma (GBM) patients require the administration of dexamethasone (DEXA) to reduce brain inflammation. DEXA activates the glucocorticoid receptor (GR), which can consequently crosstalk with the mineralocorticoid receptor (MR). However, while GR signaling is well studied in GBM,...
Autores principales: | Aldaz, Paula, Fernández-Celis, Amaya, López-Andrés, Natalia, Arozarena, Imanol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584062/ https://www.ncbi.nlm.nih.gov/pubmed/34769089 http://dx.doi.org/10.3390/ijms222111656 |
Ejemplares similares
-
Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Aldaz, Paula, et al.
Publicado: (2021) -
Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury
por: Nakamura, Toshifumi, et al.
Publicado: (2022) -
Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein
por: Jover, Eva, et al.
Publicado: (2021) -
Beneficial Effects of Mineralocorticoid Receptor Antagonism on Myocardial Fibrosis in an Experimental Model of the Myxomatous Degeneration of the Mitral Valve
por: Ibarrola, Jaime, et al.
Publicado: (2020) -
Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice
por: Palacios-Ramirez, Roberto, et al.
Publicado: (2022)